Phase 3 N=67 Long-term Study of Alogliptin as an Add-on to Rapid-Acting Insulin Secretagogues in Type 2 Diabetes
Diabetes Mellitus
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 57; 5; 6; 0 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=30 Single Site, Masked, Randomized, Controlled Study to Assess Efficacy of Osurdex as Adjunct to Avastin Compared With Avastin Alone in the Treatment of Patients With Macular Edema Due to Central or Branch Retinal Vein Occlusion
Retinal Vein Occlusions
Primary: Change From Baseline Visual Acuity at 6 Months — 2.3; 0.1 ETDRS score
N/A N=62 Comparison Between Pyloric Preserving and Non-Pyloric Preserving Bariatric Surgery With Glucose Challenge
Hypoglycemia · Obesity
Primary: Mean Serum Glucose Levels — 123.1; 157.5; 103.2; 138 mg/dl
Phase 1 N=40 Study of the Tdap Combined Vaccine (ADACEL™) as a Booster Dose in Healthy Adults and Children in China
Diphtheria · Tetanus · Pertussis
Primary: Number of Participants Reporting Serious Adverse Events and Grade 3 Adverse Reactions Following a Single Booster Dose of Adacel™ Vaccine — 0; 0; 0; 3 Participants
N/A N=57 Anesthesia Preference for Intravitreal Injection: Topical or Subconjunctival
Age-related Macular Degeneration · Central Retinal Vein Occlusion · Diabetic Macular Edema
Primary: Number of Participants Who Preferred Subconjunctival Anesthetic at the Third Follow-up Visit — 50 participants
N/A N=60 A 4-week, Randomized, Rater-blinded, Parallel Study to Evaluate Quetiapine in Improving Sleep Quality of Schizophrenia
Schizophrenia
Primary: Percentage of Slow Wave Sleep — 10.5; 8.6; 9.2; 6.3 percentage of slow wave sleep
Phase 3 N=908 Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding.
Rheumatoid Arthritis
Primary: Proportion of Patients With ACR20 at Week 24, Comparison Between Fostamatinib and Placebo — 39.6; 39.6; 24.5 Percentage of responders — p=<0.001
Phase 4 N=19 Natalizumab De-escalation With Interferon Beta-1b
Relapsing-remitting Multiple Sclerosis
Primary: Number of Days Until First On-study Relapse — NA; 103 days — p=0.125
N/A N=198 Evaluation of the Effectiveness of Two Marketed Multi-Purpose Solutions for Silicone Hydrogel Contact Lenses - Study 1
Myopia · Hyperopia · Contact Lens Comfort
Primary: Corneal Staining — 1.9; 2.8 Units on a scale
Phase 2 N=113 Dose-Response Study of Ibalizumab (Monoclonal Antibody) Plus Optimized Background Regimen in Patients With HIV-1
HIV
Primary: The Proportion of Patients Achieving Undetectable Viral Loads at Week 24. — 44; 28 percentage of participants
Phase 2 N=92 A Study to Assess the Effectiveness, Safety, and Pharmacokinetics of TMC435 in Combination With Peginterferon Alfa-2a and Ribavirin in Hepatitis-C Infected Patients
Hepatitis C, Chronic
Primary: Change in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels From Baseline to Week 4 — -5.23; -5.24; -2.83 log10 IU/mL
N/A N=4,065 Sitagliptin/Metformin (JANUMET) Re-examination Study (0431A-182)
Type 2 Diabetes Mellitus
Primary: Percentage of Participants With Any Adverse Experience — 3.74 Percentage of participants
Phase 4 N=84 A Comparison of Postoperative Tramadol Versus Acetaminophen With Codeine in Children Undergoing Tonsillectomy
Tonsillitis · Pain
Primary: Efficacy of Two Different Liquid Pain Medications: Tramadol vs. Codeine/Acetaminophen During the Post-tonsillectomy Recovery Period. — 1.5; 1 days
Phase 1 N=62 Safety Tolerability and Pharmacokinetic of BI 411034
Healthy
Primary: Number of Participants With Drug Related AEs — 1; 0; 0; 1 participants
N/A N=300 Clinical Protocol SeCore, uTYPE and 3500 Dx System
Human Leukocyte Antigens (HLA)
Primary: All SeCore® Kits,Primary Analysis of Concordance Rate (Clopper-Pearson CI) — 99.6 percentage of concordant alleles